Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Timothy Paul Heffernan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3166-8922; OpenAlex author ID A5065349307, A5109602568. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 4 papers · 2025: 2 papers · 2026: 7 papers

Papers 26

  1. Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102613↗
  2. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  3. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  4. CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. Co-author DOI 10.1038/s44318-026-00854-5↗
  5. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-3849↗
  6. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  7. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.01.756025↗
  8. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
  9. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  10. A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. Co-author DOI 10.1080/19420862.2024.2438173↗
  11. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer Co-author DOI 10.1101/2024.10.21.619543↗
  12. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  13. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  14. KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Co-author DOI 10.1016/j.ccell.2023.07.002↗
  15. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41467-021-24798-y↗
  16. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  17. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  18. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Co-author DOI 10.1101/2020.09.17.302034↗
  19. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  20. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
  21. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  22. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
  23. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
  24. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
  25. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
  26. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giulio Francesco Draetta · 15 shared papers, 2014–2026 · strength 1.52
  2. Haoqiang Ying · 14 shared papers, 2014–2026 · strength 1.49
  3. Andrea Viale · 14 shared papers, 2014–2026 · strength 1.40
  4. Wantong Yao · 13 shared papers, 2014–2026 · strength 1.35
  5. Anirban Maitra · 13 shared papers, 2016–2026 · strength 1.33
  6. Alessandro Carugo · 13 shared papers, 2014–2026 · strength 1.31
  7. Giannicola Genovese · 11 shared papers, 2014–2026 · strength 1.14
  8. Huamin Wang · 11 shared papers, 2014–2026 · strength 1.04
  9. Virginia Giuliani · 9 shared papers, 2014–2026 · strength 1.03
  10. Jason B. Fleming · 12 shared papers, 2014–2026 · strength 1.00
  11. Ronald Anthony Depinho · 9 shared papers, 2014–2026 · strength 0.79
  12. Michael P. Kim · 6 shared papers, 2019–2024 · strength 0.60
  13. Ya’an Kang · 7 shared papers, 2014–2026 · strength 0.59
  14. I-Lin Ho · 5 shared papers, 2019–2026 · strength 0.59
  15. Paola A. Guerrero · 4 shared papers, 2020–2026 · strength 0.57
  16. Ziheng Chen · 4 shared papers, 2019–2026 · strength 0.51
  17. Kathleen M. McAndrews · 3 shared papers, 2023–2026 · strength 0.48
  18. Krishnan K. Mahadevan · 3 shared papers, 2023–2026 · strength 0.48
  19. Raghu Kalluri · 3 shared papers, 2023–2026 · strength 0.48
  20. Francesca Citron · 3 shared papers, 2024–2026 · strength 0.45
  21. Piergiorgio Pettazzoni · 7 shared papers, 2014–2026 · strength 0.43
  22. Jun Yao · 4 shared papers, 2019–2025 · strength 0.41
  23. Yongkun Wei · 2 shared papers, 2025–2026 · strength 0.39
  24. Andrew J. Aguirre · 2 shared papers, 2026 · strength 0.39
  25. Aislyn P. Schalck · 2 shared papers, 2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.